DSIP (Delta Sleep-Inducing Peptide)
Also: Delta Sleep-Inducing Peptide, Delta Sleep Inducing Peptide, Delta-sleep-inducing peptide, DSIP nonapeptide
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
DSIP (delta sleep-inducing peptide) is a short, naturally occurring nonapeptide first described in the 1970s in early animal studies of sleep physiology, from which its name derives. It is discussed in the research literature largely in connection with sleep and circadian regulation, stress-hormone (HPA-axis) signaling, and related neuromodulatory processes, though its precise biological role and mechanism remain poorly defined. The available evidence is limited, much of it decades old and preclinical, and findings have been inconsistent across studies. This profile is an educational, research-use-only summary and is not a recommendation for any human or animal use.
Mechanism as described in the literature
DSIP is a small endogenous peptide (a nine-amino-acid sequence) that has been detected in nervous-system and peripheral tissues and is described in the literature as a putative neuromodulator. Unlike many better-characterized signaling peptides, no specific DSIP receptor has been conclusively identified, and the molecular pathways through which it might act are not well established. Mechanistic discussion in preclinical and in-vitro reports has touched on possible interactions with sleep-related and circadian signaling, the hypothalamic-pituitary-adrenal (stress) axis, and various neuroendocrine and antioxidant-related processes.
Because the proposed mechanisms are largely inferred from older animal and tissue studies rather than from well-replicated, controlled human work, they should be read as hypotheses under investigation rather than settled biology. Reports vary in study design, peptide preparation, and outcome measures, which complicates interpretation and limits how far any single mechanistic account can be generalized.
Research areas
- Sleep architecture and circadian regulation (the historical context in which DSIP was originally described)
- Stress and hypothalamic-pituitary-adrenal (HPA) axis signaling, examined in preclinical models
- Thermoregulation and other neuroendocrine processes discussed at a mechanistic level
- Neuroprotection- and oxidative-stress-related endpoints examined in animal and in-vitro studies
- Nociception and pain-signaling pathways explored in early experimental work
Documentation notes
References
Frequently asked questions
What is DSIP?+
DSIP, or delta sleep-inducing peptide, is a short naturally occurring peptide first described in the 1970s during early animal research on sleep physiology. It is discussed in the scientific literature as a possible neuromodulator, but its biological role is not well defined. This profile is educational and research-use-only and does not endorse any use.
Does the name mean DSIP is a proven sleep aid?+
No. The name reflects the experimental context in which the peptide was originally identified, not a demonstrated, reliable effect. The evidence linking DSIP to sleep outcomes is limited, largely preclinical or historical, and inconsistent, and it should not be interpreted as showing that DSIP treats sleep problems or any other condition.
How strong is the evidence on DSIP?+
Limited. Most data come from older animal and in-vitro studies, with relatively few small human investigations and no clearly established mechanism or receptor. Findings require careful interpretation, and conclusions about real-world effects cannot be drawn from the current literature.